DGAP-News: Aegerion Pharmaceuticals, Inc.
Aegerion Pharmaceuticals Observes World Lipodystrophy Day
31.03.2016 / 08:59
The issuer is solely responsible for the content of this announcement.
—————————————————————————
CAMBRIDGE, Mass., 2016-03-31 09:00 CEST (GLOBE NEWSWIRE) —
Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company
focused on the development and commercialization of novel therapeutics to treat
debilitating rare diseases, announced today its observance of World
Lipodystrophy Day.
Chief Executive Officer Mary Szela said, ‘We support the Association of
Families Affected by Lipodystrophies in Spain, Europe & Latin America (AELIP),
Lipodystrophy United (LU), and others in the lipodystrophy community in their
objective to increase awareness and diagnosis of this serious and often
undiagnosed rare disease. Education is an important step towards making an
impact for people affected by lipodystrophy.’
Lipodystrophy is a group of rare diseases characterized by the lack of fat
tissue. In some patients, it is genetic, and in others it may be acquired. It
can be characterized by a widespread lack of fat tissue under the skin
(generalized lipodystrophy) or limited lack of fat tissue (partial
lipodystrophy). This loss of fat tissue might cause a deficit in the hormone
leptin leading to multiple medical complications such as severe metabolic
complications.
‘Lipodystrophies are rare diseases, meaning they can be difficult to diagnose
correctly and therefore treat properly and efficiently,’ said David
Araujo-Vilar, MD, Professor of Medicine, Division of Endocrinology and
Nutrition, University Clinical Hospital of Santiago de Compostela (Spain). ‘A
common feature of most lipodystrophies is the predisposition to diabetes
mellitus, dyslipidemia and cardiovascular diseases. Through increased awareness
and education, physicians can more accurately diagnose and effectively treat
these serious diseases.’
‘Our objectives for World Lipodystrophy Day include raising awareness of the
public health problem posed by lipodystrophy, implementing actions that impact
the challenges faced by patients with lipodystrophy and their families, and
joining together with the community to pool resources and improve care for
those affected by this rare disease,’ said Naca Perez de Tudela, president of
AELIP.
To learn more about lipodystrophy, visit www.aelip.org,
www.lipodystrophyunited.org or http://www.lipodystrophy.co.uk.
About Aegerion Pharmaceuticals
Aegerion Pharmaceuticals is a biopharmaceutical company dedicated to the
development and commercialization of innovative therapies for patients with
debilitating, rare diseases. For more information about the company, please
visit www.aegerion.com.
CONTACT:
Aegerion Pharmaceuticals, Inc.
Amanda Murphy
Associate Director, Investor & Public Relations
857-242-5024
News Source: NASDAQ OMX
—————————————————————————
31.03.2016 Dissemination of a Corporate News, transmitted by DGAP – a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
—————————————————————————
Language: English
Company: Aegerion Pharmaceuticals, Inc.
United States
ISIN: US00767E1029
End of News DGAP News Service
—————————————————————————
450025 31.03.2016
